TTrialPathMatch Me to Trials
← Back to trials
RecruitingHepatitis B, Chronic

Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion

Eligible age

18–65 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this observational study is to learn about the HBsAg reversion rate at 48 weeks off treatment in HBsAg-negative patients by HBsAg NEXT assay which has improved sensitivity compared to current ARCHITECT HBsAg Assay. The main question it aims to answer is: What's the HBsAg reversion rate at 48 weeks off treatment in HBsAg-negative patients by HBsAg NEXT assay? HBsAg NEXT assay technology (lower limit of detection for HBsAg is 0.005 IU/ml) and current ARCHITECT HBsAg assay (lower limit of detection for HBsAg is 0.05 IU/ml) are applied for HBsAg detection in patients achieving functional cure, and to compare the difference in HBsAg reversion rate 48 weeks off treatment under the two types of criteria.

Sponsor: Huashan Hospital

You may qualify if…

  • ✓ HBsAg-negative by Abbott's HBsAg Test and HBeAg-negative;
  • ✓ Having serum specimens retained at baseline and at 48 weeks off treatment follow up;
  • ✓ Being willing to follow up regularly for 1 year.

You may not qualify if…

  • ✕ Patients with hepatitis B cirrhosis in the compensated and decompensated stages: this includes patients with a clear history of cirrhosis (imaging or histological evidence) or Child-Pugh score ≥5 prior to NUC treatment, or who have had complications of the decompensated stage of cirrhosis, such as ascites, hepatic encephalopathy, or ruptured oesophago-gastric fundal varices bleeding;
  • ✕ Combined HAV, HCV, HDV, HEV, HIV infections, alcoholic liver disease, inherited metabolic liver disease, pharmacological liver disease, non-alcoholic fatty liver disease, autoimmune liver disease and other chronic liver diseases;
  • ✕ Primary hepatocellular carcinoma or those with AFP greater than 100 ng/ml at screening and imaging suggestive of possible malignant hepatic occupancy; or patients with AFP greater than 100 ng/ml for a sustained period of 3 months;
  • ✕ Patients with a combination of other malignant tumours (excluding those who have been cured);
  • ✕ Patients with severe diseases or uncontrolled disease
  • ✕ Those who are also participating in other clinical studies;
  • ✕ Patients deemed unsuitable by the investigator to participate in this study.

Source: ClinicalTrials.gov · NCT06550622 · last updated 2024-08-13